CA3237625A1 - Kif18a inhibitor - Google Patents
Kif18a inhibitor Download PDFInfo
- Publication number
- CA3237625A1 CA3237625A1 CA3237625A CA3237625A CA3237625A1 CA 3237625 A1 CA3237625 A1 CA 3237625A1 CA 3237625 A CA3237625 A CA 3237625A CA 3237625 A CA3237625 A CA 3237625A CA 3237625 A1 CA3237625 A1 CA 3237625A1
- Authority
- CA
- Canada
- Prior art keywords
- hydrocarbyl
- compound
- solvate
- isomer
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111399876 | 2021-11-19 | ||
| CN202111399876.4 | 2021-11-19 | ||
| CN202210225663.8 | 2022-03-09 | ||
| CN202210225663 | 2022-03-09 | ||
| CN202210667619.2 | 2022-06-13 | ||
| CN202210667619 | 2022-06-13 | ||
| PCT/CN2022/132954 WO2023088441A1 (zh) | 2021-11-19 | 2022-11-18 | Kif18a抑制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3237625A1 true CA3237625A1 (en) | 2023-05-25 |
Family
ID=86396297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3237625A Pending CA3237625A1 (en) | 2021-11-19 | 2022-11-18 | Kif18a inhibitor |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4434979A4 (https=) |
| JP (1) | JP2024542199A (https=) |
| KR (1) | KR20240108489A (https=) |
| CN (1) | CN118215657A (https=) |
| AU (1) | AU2022389558A1 (https=) |
| CA (1) | CA3237625A1 (https=) |
| MX (1) | MX2024005996A (https=) |
| WO (1) | WO2023088441A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA54543A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| IL310863A (en) | 2021-08-26 | 2024-04-01 | Volastra Therapeutics Inc | Spiro indoline inhibitors of kif18a |
| WO2024022508A1 (zh) * | 2022-07-29 | 2024-02-01 | 武汉人福创新药物研发中心有限公司 | Kif18a抑制剂及用途 |
| TW202416973A (zh) | 2022-08-18 | 2024-05-01 | 美商雅客森醫療公司 | Ｋｉｆ１８ａ抑制劑及其用途 |
| WO2024083208A1 (zh) * | 2022-10-21 | 2024-04-25 | 杭州邦顺制药有限公司 | Kif18a蛋白抑制剂 |
| WO2024114730A1 (zh) * | 2022-11-30 | 2024-06-06 | 微境生物医药科技(上海)有限公司 | 一种用于癌症治疗的药物组合物 |
| EP4628486A1 (en) * | 2022-12-02 | 2025-10-08 | Shenzhen Zhongge Biological Technology Co., Ltd. | Amide or urea compound |
| CN120569373A (zh) * | 2023-01-05 | 2025-08-29 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和医药上的用途 |
| WO2024244972A1 (zh) * | 2023-05-30 | 2024-12-05 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和用途 |
| CN121532380A (zh) * | 2023-07-21 | 2026-02-13 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和用途 |
| CN121752573A (zh) * | 2023-08-02 | 2026-03-27 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| WO2025036479A1 (zh) * | 2023-08-16 | 2025-02-20 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| WO2025190888A1 (en) * | 2024-03-12 | 2025-09-18 | F. Hoffmann-La Roche Ag | Macrocyclic kif18a inhibitors and their use thereof |
| WO2025201407A1 (zh) * | 2024-03-27 | 2025-10-02 | 上海齐鲁制药研究中心有限公司 | 驱动蛋白kif18a抑制剂及其使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO395396A0 (en) * | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| JP2022513967A (ja) * | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド |
| MA54543A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| AU2019401495B2 (en) * | 2018-12-20 | 2025-06-26 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| JP7686559B2 (ja) * | 2018-12-20 | 2025-06-02 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤 |
| EP4007638A1 (en) * | 2019-08-02 | 2022-06-08 | Amgen Inc. | Pyridine derivatives as kif18a inhibitors |
| EP4007752B1 (en) * | 2019-08-02 | 2025-09-24 | Amgen Inc. | Kif18a inhibitors |
| EP4007753B1 (en) * | 2019-08-02 | 2025-09-24 | Amgen Inc. | Kif18a inhibitors |
| MX2022012992A (es) * | 2020-04-14 | 2022-11-08 | Amgen Inc | Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas. |
| CN120265625A (zh) * | 2021-09-24 | 2025-07-04 | 泽农医药公司 | 作为钠通道活化剂的吡啶基乙酰胺衍生物 |
-
2022
- 2022-11-18 AU AU2022389558A patent/AU2022389558A1/en active Pending
- 2022-11-18 CN CN202280076424.9A patent/CN118215657A/zh active Pending
- 2022-11-18 JP JP2024529504A patent/JP2024542199A/ja active Pending
- 2022-11-18 WO PCT/CN2022/132954 patent/WO2023088441A1/zh not_active Ceased
- 2022-11-18 MX MX2024005996A patent/MX2024005996A/es unknown
- 2022-11-18 CA CA3237625A patent/CA3237625A1/en active Pending
- 2022-11-18 EP EP22894970.7A patent/EP4434979A4/en active Pending
- 2022-11-18 KR KR1020247020178A patent/KR20240108489A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022389558A1 (en) | 2024-05-23 |
| JP2024542199A (ja) | 2024-11-13 |
| MX2024005996A (es) | 2024-05-30 |
| CN118215657A (zh) | 2024-06-18 |
| EP4434979A1 (en) | 2024-09-25 |
| EP4434979A4 (en) | 2025-10-29 |
| WO2023088441A1 (zh) | 2023-05-25 |
| KR20240108489A (ko) | 2024-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3237625A1 (en) | Kif18a inhibitor | |
| ES2494918T3 (es) | Compuestos de guanidina y su uso como componentes de unión para receptores 5-HT5 | |
| AU2001262318B2 (en) | Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament | |
| CA3171774C (en) | AMINE DERIVATIVE PYRIMIDINE OR SUBSTITUTED PYRIDINE, RELATED COMPOSITION AND RELATED MEDICAL USE | |
| JPS58192890A (ja) | 新規な７−アミノチアゾリルアセタミドセフアロスポラン酸のアルキルオキシム誘導体、その製造方法および医薬組成物 | |
| CN111961057A (zh) | 一种α构型核苷及其在治疗猫冠状病毒感染的应用 | |
| CA2908695A1 (en) | Ppar agonists | |
| CA2978158A1 (en) | Riluzole prodrugs and their use | |
| DE69809782T2 (de) | Npy antagonisten | |
| RU2263113C2 (ru) | Производные 8,8а-дигидроиндено [1,2-d]тиазола, содержащие в положении 2 заместитель с сульфонамидной или сульфоновой структурой, способ их получения и их применение в качестве лекарственного средства | |
| BRPI0611435A2 (pt) | derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos | |
| CA3173354A1 (en) | A 2,3-dihydrofuro[2,3-c]pyridine-3-carboxamide compound and its antiviral use | |
| CA3225135A1 (en) | 3,4-methylenedioxymethamphetamine and related psychedlics and uses thereof | |
| JP2018505199A (ja) | （Ｓ）−５−ベンジル−Ｎ−（５−メチル−４−オキソ−２，３，４，５テトラヒドロベンゾ［ｂ］［１，４］オキサゼピン−３−イル）−４Ｈ−１，２，４−トリアゾール−３−カルボキサミドの結晶形 | |
| PT1652843E (pt) | Derivados amida | |
| CA2912064A1 (en) | Compounds for inhibiting drug-resistant strains of hiv-1 integrase | |
| MXPA02003477A (es) | Derivados de indeno-, nafto-, y benzociclohepta-dihidrotiazol, la produccion de los mismos y su uso como medicamentos anorecticos. | |
| AU2014230583A1 (en) | Guanidinobenzoic acid ester compound | |
| JP6411355B2 (ja) | 抗菌剤 | |
| AU766295B2 (en) | Utilization of polycyclic 2-amino-thiazole systems in the production of medicaments for prophylaxis or treatment of obesity | |
| AT406773B (de) | Neues salz von 7-(2-(aminothiazol-4yl)-2- | |
| CN109970675A (zh) | 一组硫脲化合物及其制备方法和应用 | |
| US3259635A (en) | 7-hydroxy coumarin derivative | |
| CN104876849B (zh) | 一种吲哚衍生物及其用途 | |
| EP0160546A2 (en) | Cephalosporin compounds, and their production, and medicaments containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - SMALL Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241111 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241111 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251105 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251105 |